[go: up one dir, main page]

GB201903237D0 - Method - Google Patents

Method

Info

Publication number
GB201903237D0
GB201903237D0 GBGB1903237.4A GB201903237A GB201903237D0 GB 201903237 D0 GB201903237 D0 GB 201903237D0 GB 201903237 A GB201903237 A GB 201903237A GB 201903237 D0 GB201903237 D0 GB 201903237D0
Authority
GB
United Kingdom
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1903237.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autolus Ltd
Original Assignee
Autolus Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autolus Ltd filed Critical Autolus Ltd
Priority to GBGB1903237.4A priority Critical patent/GB201903237D0/en
Publication of GB201903237D0 publication Critical patent/GB201903237D0/en
Priority to EP20709693.4A priority patent/EP3934666A1/en
Priority to CN202080019321.XA priority patent/CN113543792A/en
Priority to CA3131839A priority patent/CA3131839A1/en
Priority to PCT/GB2020/050535 priority patent/WO2020183131A1/en
Priority to JP2021552866A priority patent/JP7602475B2/en
Priority to US17/436,673 priority patent/US20220145325A1/en
Priority to AU2020235395A priority patent/AU2020235395A1/en
Priority to US17/746,664 priority patent/US12269860B2/en
Priority to JP2024042171A priority patent/JP2024069539A/en
Priority to US19/073,904 priority patent/US20250296976A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
GBGB1903237.4A 2019-03-08 2019-03-08 Method Ceased GB201903237D0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
GBGB1903237.4A GB201903237D0 (en) 2019-03-08 2019-03-08 Method
AU2020235395A AU2020235395A1 (en) 2019-03-08 2020-03-06 Compositions and methods comprising engineered chimeric antigen receptor and modulator of CAR
PCT/GB2020/050535 WO2020183131A1 (en) 2019-03-08 2020-03-06 Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
CN202080019321.XA CN113543792A (en) 2019-03-08 2020-03-06 Compositions and methods comprising engineered chimeric antigen receptors and CAR modulators
CA3131839A CA3131839A1 (en) 2019-03-08 2020-03-06 Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
EP20709693.4A EP3934666A1 (en) 2019-03-08 2020-03-06 Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
JP2021552866A JP7602475B2 (en) 2019-03-08 2020-03-06 Compositions and methods involving engineered chimeric antigen receptors and modulators of CAR
US17/436,673 US20220145325A1 (en) 2019-03-08 2020-03-06 Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
US17/746,664 US12269860B2 (en) 2019-03-08 2022-05-17 Compositions and methods comprising engineered chimeric antigen receptor and modulator of CAR
JP2024042171A JP2024069539A (en) 2019-03-08 2024-03-18 Compositions and methods involving engineered chimeric antigen receptors and modulators of CAR
US19/073,904 US20250296976A1 (en) 2019-03-08 2025-03-07 Compositions and methods comprising engineered chimeric antigen receptor and modulator of car

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1903237.4A GB201903237D0 (en) 2019-03-08 2019-03-08 Method

Publications (1)

Publication Number Publication Date
GB201903237D0 true GB201903237D0 (en) 2019-04-24

Family

ID=66218271

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1903237.4A Ceased GB201903237D0 (en) 2019-03-08 2019-03-08 Method

Country Status (1)

Country Link
GB (1) GB201903237D0 (en)

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000063372A1 (en) 1999-04-16 2000-10-26 Celltech Therapeutics Limited Synthetic signalling molecules
WO2013153391A1 (en) 2012-04-13 2013-10-17 Ucl Business Plc Polypeptide useful in adoptive cell therapy
WO2015052538A1 (en) 2013-10-10 2015-04-16 Ucl Business Plc Chimeric antigen receptor
WO2015075489A2 (en) 2013-11-20 2015-05-28 Medicontur Orvostechnikai Kft. Preloaded injector with cartridge for storing and injecting hydrophobic intraocular lenses
WO2015075470A1 (en) 2013-11-21 2015-05-28 Ucl Business Plc Cell
WO2015132604A1 (en) 2014-03-06 2015-09-11 Ucl Business Plc Chimeric antigen receptor
WO2015150771A1 (en) 2014-04-01 2015-10-08 Ucl Business Plc Chimeric antigen receptor (car) signalling system
WO2016030691A1 (en) 2014-08-29 2016-03-03 Ucl Business Plc Signalling system
WO2016090337A1 (en) 2014-12-05 2016-06-09 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof
WO2016102965A1 (en) 2014-12-24 2016-06-30 Ucl Business Plc Cell
WO2016124930A1 (en) 2015-02-05 2016-08-11 Ucl Business Plc Signalling system
WO2016135470A1 (en) 2015-02-24 2016-09-01 Ucl Business Plc Chimeric protein
WO2016139487A1 (en) 2015-03-05 2016-09-09 Ucl Business Plc Chimeric antigen receptor (car) comprising a cd19-binding domain
WO2016150771A1 (en) 2015-03-20 2016-09-29 Novozymes A/S Droplet-based selection by injection
WO2016193698A1 (en) 2015-06-01 2016-12-08 Mountt&C Holdings Limited Hydraulic breaker, in particular for an excavator
WO2017029512A1 (en) 2015-08-20 2017-02-23 Autolus Ltd Chimeric cytokine receptor
US20180064785A1 (en) 2016-09-07 2018-03-08 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of bph
WO2018115866A1 (en) 2016-12-21 2018-06-28 Autolus Limited Transcription system
WO2018193231A1 (en) 2017-04-18 2018-10-25 Autolus Limited Cell

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000063372A1 (en) 1999-04-16 2000-10-26 Celltech Therapeutics Limited Synthetic signalling molecules
WO2013153391A1 (en) 2012-04-13 2013-10-17 Ucl Business Plc Polypeptide useful in adoptive cell therapy
WO2015052538A1 (en) 2013-10-10 2015-04-16 Ucl Business Plc Chimeric antigen receptor
WO2015075489A2 (en) 2013-11-20 2015-05-28 Medicontur Orvostechnikai Kft. Preloaded injector with cartridge for storing and injecting hydrophobic intraocular lenses
WO2015075470A1 (en) 2013-11-21 2015-05-28 Ucl Business Plc Cell
WO2015132604A1 (en) 2014-03-06 2015-09-11 Ucl Business Plc Chimeric antigen receptor
WO2015150771A1 (en) 2014-04-01 2015-10-08 Ucl Business Plc Chimeric antigen receptor (car) signalling system
WO2016030691A1 (en) 2014-08-29 2016-03-03 Ucl Business Plc Signalling system
WO2016090337A1 (en) 2014-12-05 2016-06-09 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof
WO2016102965A1 (en) 2014-12-24 2016-06-30 Ucl Business Plc Cell
WO2016124930A1 (en) 2015-02-05 2016-08-11 Ucl Business Plc Signalling system
WO2016135470A1 (en) 2015-02-24 2016-09-01 Ucl Business Plc Chimeric protein
WO2016139487A1 (en) 2015-03-05 2016-09-09 Ucl Business Plc Chimeric antigen receptor (car) comprising a cd19-binding domain
WO2016150771A1 (en) 2015-03-20 2016-09-29 Novozymes A/S Droplet-based selection by injection
WO2016193698A1 (en) 2015-06-01 2016-12-08 Mountt&C Holdings Limited Hydraulic breaker, in particular for an excavator
WO2017029512A1 (en) 2015-08-20 2017-02-23 Autolus Ltd Chimeric cytokine receptor
US20180064785A1 (en) 2016-09-07 2018-03-08 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of bph
WO2018115866A1 (en) 2016-12-21 2018-06-28 Autolus Limited Transcription system
WO2018193231A1 (en) 2017-04-18 2018-10-25 Autolus Limited Cell

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
"UniProtKB", Database accession no. P29350
"UniProtKB", Database accession no. P35235-1
BEDINGER ET AL.: "describes various human monoclonal antibodies that neutralize multiple TGFβ isaforms", MABS, vol. 8, no. 2, 2016, pages 389 - 404
DONNELLY ET AL., J. GEN. VIROL., vol. 82, 2001, pages 1027 - 1041
GRADA, MΟΊ THER NUCLEIC ACIDS, vol. 2, 2013, pages e105
HASO ET AL., BLOOD, vol. 121, no. 7, 2013
JUNHANS ET AL., PROSTATE, vol. 76, 2016, pages 1257 - 1270
KIRN: "engineered TGFβ monomer that functions as a dominant negative to block TGFP signalling", J. BIOL. CHEM., 2017
KLOSS ET AL., MOL. THER., vol. 28, 2018, pages 1855 - 1866
LEEN ET AL., MOL. THER., vol. 22, 2014, pages 1211 - 1220

Similar Documents

Publication Publication Date Title
SG11202112409WA (en) Method
GB201911286D0 (en) Method
GB201913997D0 (en) Method
GB201909562D0 (en) Method
GB201910759D0 (en) Method
GB201917742D0 (en) Method
GB201907782D0 (en) Method
GB201900940D0 (en) Method
GB201900647D0 (en) Method
GB201917060D0 (en) Method
GB201912863D0 (en) Novel method
IL289648A (en) Method
GB201917638D0 (en) Method
GB201913970D0 (en) Method
GB201910404D0 (en) Method
GB201909131D0 (en) Method
GB201906768D0 (en) Method
GB201901532D0 (en) Method
GB202007297D0 (en) Method
GB2587925B (en) Method
GB201918290D0 (en) Method
GB201917824D0 (en) Method
GB201917806D0 (en) Method
GB201917599D0 (en) Method
GB201916390D0 (en) Method

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)